A drug combination for tumor immunotherapy

A drug and tumor technology, which is applied in the field of drug combination of tumor immunotherapy, can solve the problem that patients cannot respond to immunotherapy, and achieve the effect of enriching types, improving the effect and improving the effect

Active Publication Date: 2022-05-03
XIAMEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tumor immunotherapy, as a new type of cancer treatment, has a significant effect on some patients. Unfortunately, most patients cannot respond to immunotherapy alone clinically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug combination for tumor immunotherapy
  • A drug combination for tumor immunotherapy
  • A drug combination for tumor immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] 1.[ 18 F] Synthesis of FDG

[0058] [ 18 F] FDG was synthesized by the IBA automation module. Based on the premise of trifluoromannose, the method of alkali hydrolysis chemical synthesis. Step 1 is the nucleophilic fluorination reaction: the cyclotron produces [ 18 F]F - , under helium transport, [ 18 F]F - Adsorbed onto the QMASep-Pak anion exchange column, under the action of a vacuum pump, take a mixture of potassium carbonate (6mg / mL) dissolved in water and phase transfer catalyst K2.2.2 (20mg / mL) dissolved in acetonitrile ,Will[ 18 F]F - Eluted into the reaction vial. [ 18 F]F - The nucleophilic activity of ions is one of the key factors affecting the reaction yield, so it is very important to remove water in the reaction system. Dry [ 18 F]F - , catalyst amino polyether (K2.2.2) to chelate potassium ions in the system, so that [ 18 F]F - It is exposed to increase its nucleophilic activity (activation of fluoride ions), followed by a nucleophilic fl...

Embodiment 2

[0066] The following is the determination of the impact of different nuclides on the expression of PD-L1 and the markers synthesized by the method of the above-mentioned Example 1[ 18 F]FDG and 99m Description of the distribution and therapeutic effect of Tc-RGD in vivo:

[0067] 1. Flow cytometry to detect the effect of different nuclides on the expression of PD-L1

[0068] CT26, MC38, 4T1 and B16F10 tumor cells were plated in six-well plates overnight, and 740kBq of radionuclide Na was added to each well 18 F, The cells of the control group were added with an equal volume of normal saline, and the cells of the experimental group and the control group were cultured in different incubators to ensure that the control group was not affected. After incubation at different time points (0.5h, 2h, 4h, 8h and 24h), the cells were collected and washed twice with ice-cold PBS, then stained with anti-PD-L1 antibody (abcam, ab238697), and restained overnight Fluorescent secondary anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a drug combination for tumor immunotherapy, which provides a new application of the radionuclide or its marker, and the new application is the application of the radionuclide or its marker in remodeling the tumor immune microenvironment. The present invention also provides a drug combination for human or mouse tumor immunotherapy, which is composed of a radionuclide or its marker and an immune checkpoint inhibitor in a specific ratio. The present invention also provides a kit for tumor immunotherapy, containing the drug combination for tumor immunotherapy of human or mouse. The drug combination provided by the present invention can reshape the immune microenvironment of the tumor while detecting the tumor through the radionuclide or its marker, and then significantly slow down the tumor growth rate and improve the survival period through the immune checkpoint inhibitor. The drug combination of the present invention has good synergistic effect, and the kit of the present invention is convenient to use and easy to realize clinical promotion.

Description

technical field [0001] The invention belongs to the field of chemical drugs, in particular to a drug combination for tumor immunotherapy. Background technique [0002] In recent years, malignant tumors have become one of the major public health problems that seriously threaten human health. In my country, the incidence and mortality of cancer rank first in the world! Therefore, it is still an arduous task to reduce the incidence and mortality of malignant tumors in my country. [0003] A large number of clinical practices have proved that the combination of early diagnosis and early treatment can reduce the mortality of cancer patients and significantly prolong the life span of cancer patients. Early malignant tumors usually lack obvious clinical signs, and imaging examination is the main means of early diagnosis. High-resolution molecular imaging techniques PET and SPECT combined with highly sensitive and highly specific radionuclide-labeled probes are expected to reflec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K51/04A61K51/08A61K45/06A61K39/395A61P35/00A61K101/02A61K103/10
CPCA61K51/0491A61K51/082A61K45/06A61K39/39558A61P35/00A61K2300/00
Inventor 张现忠文雪君郭志德石昌荣曾馨莹
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap